Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.

Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.

Background: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect. Methods: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 mg BID versus Placebo for seven days among 50 individ...

Full description

Bibliographic Details
Main Authors: Vinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter, Paulo Tierno, Acioly Lacerda, Alexandre Soeiro, Florentino Cardoso, Nancy Cristina Bellei, Juliana Maricato, Nathalia Mantovani, Marcella Vassao, Danilo Dias, Juliana Galinskas, Luis Mário Ramos Janini, Joanna Reis Santos-Oliveira, Alda Maria Da-Cruz, Ricardo Sobhie Diaz
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:EClinicalMedicine
Subjects:
COVID-19
Nitazoxanide
Randomized controlled clinical trial
Lymphocytes cell activation markers
Interleukins
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021002613

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021002613

Similar Items